1 FDA’s Communication of Drug Safety Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research December 7-8, 2005 Welcome – Opening Remarks.

Slides:

Advertisements

Similar presentations

DIGITAL AGE SKILLS TECHNOLOGY PROFICIENCY –Ability to use digital tools for information processing, management, and communication INFORMATION LITERACY.

Advertisements

REMS Update NORD Corporate Council Meeting May 14, 2013

FDA and Communication about Regulated Products Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee August.

Challenges for Lithuanian health system: EU accession Rytis Virbalis, MD, MPH, Senitor adviser to Committee on Health affairs Lithuanian Parliament 1.Prevention.

Critical Appraisal Skills Program

World Health Organization Conference on Developing New SPHs Jerusalem March, 2002 What should an MPH graduate be able to do at the end of the training.

Study: Statins increase life expectancy Detroit News, Associated Press

Theresa Tsosie-Robledo MS RN-BC February 15, 2012

HINARI/Health Information on the Internet (module 1.3 Part A)

FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

Prescription for Confusion: Health Literacy & Drug Warning Labels Michael S. Wolf, PhD MPH Northwestern University Terry C. Davis, PhD Louisiana State.

April 8, 2005FDLI Annual Conference 1 Labeling Prescription Drugs for Physicians and Consumers (FDA Perspective) Paul J. Seligman, MD, MPH Director, Office.

Overview of the New Content and Format Requirements for Prescription Drug Labeling.

Driving Home the Point: Medicines, Impaired Driving, and You Ali Mohamadi, MD Medical Officer Professional Affairs and Stakeholder Engagement RADD-ONDCP.

1 Drug Safety Oversight Board Update DIA Annual Meeting Philadelphia, PA June 21 st, 2006 Susan K. Cummins, MD, MPH Executive Director Drug Safety Oversight.

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

Whiteboards across the system

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

National Public Health Performance Standards Local Assessment Instrument Essential Service:9 Evaluate Effectiveness, Accessibility, and Quality of Personal.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

Translational Science in Cancer Health Disparities Research Peter Ujhazy, M.D., Ph.D. Program Director Translational Research Program Division of Cancer.

Chapter 10 Enhancing Public Relations. Public Relations  Public relations includes all activities undertaken to enhance image and create goodwill. 

Applications of IndiGO to ACOs David M Eddy MD PhD Founder and Chief Medical Officer Emeritus Archimedes San Francisco, CA ... a KAISER PERMANENTE Innovation.

1 Best Practices in Stakeholder Involvement Paul J. Seligman, M.D., M.P.H. Associate Director, Safety Policy & Communication Center for Drug Evaluation.

Communication of Drug Safety Information Food and Drug Administration Center for Drug Evaluation & Research Public Hearing December 8, 2005.

Follow-up on Abnormal Cancer Screenings: Creating a system-wide, EMR-based solution to improve patient safety and reduce medical errors Cambridge Health.

Risk Communication FDA Public Hearing Washington DC Dec 7-8, 2005 Cherif Benattia, MD President & CEO APhaRC, LLC 2008 Stone Ridge Lane Villanova, PA

Collaborative on Reducing Readmissions in Florida Medication Reconciliation: Admission and Discharge Webinar #5 June 3, :30-3:00 PM EDT.

HEALTH LITERACY MONTH WORKSHOP Tools to help find and use health information.

The Implications of Health Literacy for Customer-Centered Health Communication and Marketing Cynthia Baur, Ph.D. National Center for Health Marketing Centers.

June 24, 2003 Health Communications Progress Review Focus Area 11.

The Influenza Immunization Season: An Early Look at Communications and Media Planning Glen Nowak, Ph.D. Director, Media Relations Centers for Disease.

CDER Drug Safety Oversight Board Douglas C. Throckmorton, M.D. Deputy Director, CDER Food and Drug Administration November 5, 2005.

Shared Decision Making: Helping Patients be Partners in Their Care 2009 AHRQ Annual Meeting September 14, 2009.

1 Serious Adverse Events Following Falsely Elevated Glucose Measurements Resulting from Administration of an IGIV Product Containing Maltose BPAC Meeting,

University medical center Introducing the UMC Web Site.

Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.

Chapter 19 Manager of Information Systems. Defining Informatics Process of using cognitive skills and computers to manage information.

FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.

Sources 65 Over Next 19 Years - U.S. Dept. of Commerce, Economics and Statistics Administration. U.S. Census Bureau, May “The Next.

School for hypertensive patients as a new health promotion and disease prevention technology in hospitals and out-patient clinics MD Eganyan R.A., PhD.

Labeling and Electronic Initiatives Rachel E. Behrman M.D., M.P.H. Deputy Director, Office of Medical Policy CDER FDA Science Board, April 15, 2005.

Office of Drug Safety Updates Drug Safety and Risk Management Advisory Committee Meeting February 10, 2006 Gerald J. Dal Pan, MD, MHS Director, Office.

July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

Improving Retention Workshop Breakout Notes 2/18/2010.

1 Presentation of the Pharmaceutical Research and Manufacturers of America at FDA Part 15 Hearing on Communication of Drug Safety Information December.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.

Food and Drug Administration Drug Safety and Risk Management Advisory Committee May 5, 2004 Low Density Polyethylene Vials (LDPE) Paul Seligman, M.D.,

In the Best Interests of the Public Health... Janice Soreth, M.D. Acting Director Division of Anti-Infective Drug Products CDER/FDA.

Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.

1 RISK MANAGEMENT PUBLIC WORKSHOPS APRIL 9-11, 2003 NTSB BOARD AND CONFERENCE CENTER WASHINGTON, DC.

FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.

1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April.

Self-reflecting on our safety culture INSERT FACILITATORS NAME HERE.

Health Administration. Health Administration or Healthcare Administration is the field relating to leadership, management, and administration of public.

 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.

Awareness of the National Standards for Culturally and Linguistically Appropriate Services (CLAS) at an Academic Health Center Dr. Genny Carrillo Department.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

Facilitator: Prof. Dianne Parker University of Manchester and

FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.

Dr.farahani MD-Mph Arak health center

مرکز بهداشت شهرستان اراک انواع بيماريها و اختلالات رواني –عصبي

Professional Organizations

Please join us in celebrating. . .

Session G: ACO and Population Health Best Practices

Presentation transcript:

1 FDA’s Communication of Drug Safety Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research December 7-8, 2005 Welcome – Opening Remarks

2 FDA’s Communication of Drug Safety Paul Seligman, MD, MPH Director, Office of Pharmacoepidemiology and Statistical Science Center for Drug Evaluation and Research December 7-8, 2005 Moderator

3 Questions to Consider 1. What are the strengths and weaknesses of the following communication tools? Patient Information Sheets Healthcare Professional Information Sheets Public Health Advisories Press Releases Medwatch Listserv Safety Updates Patient Safety News CDER Internet Sites

4 Questions to Consider (cont) 2. What information is available about awareness, use, and perceptions of the effectiveness of the communication tools by healthcare professionals and by the public in general? 3. Do these tools provide the right kind and amount of risk and other information that health care professionals need to make informed decisions about whether to prescribe drug products, and that the public needs to make informed decisions about whether to use those products?

5 Questions to Consider (cont) 4. How easily accessible and understandable are FDA’s Internet-based sources of drug information? 5. To what extent do CDER’s patient-focused communication tools provide useful information for people of low health literacy skills. 6. What mechanism should CDER consider to convey risk information to special populations (e.g., elderly, non-English speaking)?